The anthracycline chemotherapeutic agent doxorubicin (DOX) is widely used to treat cancer.
However, DOX carries a high risk of adverse effects such as cardiovascular events.
The aim of this study was to explore the role of Trim65 in DOX-induced cardiotoxicity (DIC) and its underlying mechanisms.
